Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Authors' conclusion
Tirzepatide treatment significantly reduced the 10-year predicted risk of ASCVD versus placebo in patients with obesity or overweight without diabetes.
Study context
- Population
- Adults with BMI ≥30 or ≥27 kg/m² and at least one weight-related complication, without diabetes; Atherosclerotic cardiovascular disease (ASCVD) risk analysis in participants without a history of ASCVDwithout history of ASCVD
- Participants
- 2,461 adults
- Comparison
- Tirzepatide vs placebo
- Primary endpoint
- Percent change in predicted 10-year ASCVD risk score (ACC/AHA risk engine)
- Follow-up
- Baseline to week 72
Methodological detailsphase 3
- Phase 3
Primary result
As reported in the abstract
Relative change in predicted 10-year ASCVD risk
Tirzepatide
−23.5% to −16.4%
Placebo
12.7%
P < 0.001
Further findings
| Outcome | P value |
|---|---|
| Relative change in risk, intermediate-to-high baseline risk subgroupSignificantly greater with tirzepatide | P < 0.05 |
Baseline median 10-year ASCVD risk score
- Low and did not differ across groups
- 1.5%-1.6%
Relative change in risk, intermediate-to-high baseline risk subgroup
- Similar relative change but greater absolute risk reduction vs overall population
Cardiometabolic variables · 72 weeks
- Reductions in cardiometabolic variables with tirzepatide
Original publication
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis. Diabetes Obes Metab. Published 6 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →